Skip to content

Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain

Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Pain Related to Peripheral Neuropathy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05295498
Enrollment
70
Registered
2022-03-25
Start date
2022-11-04
Completion date
2026-09-30
Last updated
2024-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Neuropathy

Keywords

Peripheral neuropathy, Neuropathic pain, rTMS, analgesic effect

Brief summary

Peripheral neuropathy is a frequent condition, commonly associated with pain. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. rTMS is usually performed once a day and the whole therapy of neuropathic pain lasts one week. In a number of recent clinical trials including patients with depression and some other disorders, rTMS was delivered several times a day, which reduced the time of the whole therapy. This approach was termed an accelerated rTMS. The purpose of this study is to investigate feasibility of accelerated rTMS in treatment of neuropathic pain.

Detailed description

Peripheral neuropathy is a frequent condition, commonly associated with pain, which is often drug resistant. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity. In this method, series of magnetic stimuli are delivered to the cerebral cortex, where they turn to electric current and depolarize repetitively the targeted neurons. If the stimulation is repeated during subsequent days it is capable to modify the activity of targeted cortical area for weeks or even months and by this way to achieve therapeutic effect. rTMS is most commonly used to treat drug-resistant depression but a number of other psychiatric and neurologic conditions is increasingly being regarded as therapeutic indication for rTMS. In patients suffering from neuropathic pain rTMS is delivered with high frequency, over primary motor areas (PMA). Stimulation of PMA should result in modulation of thalamic activity, achieved by antidromic excitation of thalamocortical connections. rTMS is usually performed once a day and the whole therapy of neuropathic pain lasts one week. In a number of recent clinical trials including patients with depression and some other disorders, rTMS was delivered several times a day, which reduced the time of the whole therapy. This approach was termed an accelerated rTMS. The purpose of this study is to investigate feasibility of accelerated rTMS in treatment of neuropathic pain.

Interventions

High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.

DEVICESham repetitive transcranial magnetic stimulation

Sham stimulation to mimic the high frequency rTMS over the primary motor area.

Sponsors

Jakub Antczak
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Triple (Participant, Investigator, Outcomes Assessor). Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.

Intervention model description

Parallel Assignment. Patients will be randomly assigned to active or to sham stimulation.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of peripheral neuropathy * Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week * Score of 30 millimeter or more on the 100 millimeter visual analog scale of pain intensity at inclusion

Exclusion criteria

* Severe depression * Personality disorders and other psychiatric conditions, which could disturb the participation in the study * Cognitive deficits, which could disturb the participation in the study * Epilepsy * Presence of magnetic material in the reach of magnetic field * Pregnancy * Likelihood to get pregnant * Intracranial electrodes

Design outcomes

Primary

MeasureTime frameDescription
Visual Analogue Scale of Pain Severity after rTMSThrough study completion, an average of 1 year.An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after finishing rTMS.
Visual Analogue Scale of Pain Severity First Follow-upBefore rTMS, up to one day after finishing rTMS.An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after two weeks after finishing rTMS.
Visual Analogue Scale of Pain Severity Second Follow-upBefore rTMS, four weeks after finishing rTMS.An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after four weeks after finishing rTMS.

Secondary

MeasureTime frameDescription
Neuropathic Pain Symptoms Inventory after rTMSBefore rTMS, up to one day after finishing rTMS.Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension First Follow-upBefore rTMS, two weeks after finishing rTMS.Change from baseline strength of the foot extension to the measurement taken two weeks after finishing rTMS.
Neuropathic Pain Symptoms Inventory First Follow-upBefore rTMS, two weeks after finishing rTMS.Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken two weeks after finishing rTMS.
Neuropathic Pain Symptoms Inventory Second Follow-upBefore rTMS, four weeks after finishing rTMS.Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken four weeks after finishing rTMS.
Numeric Pain Severity Scale after rTMSBefore rTMS, up to one day after finishing rTMS.Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after finishing rTMS.
Athens Insomnia Scale after rTMSBefore rTMS, up to one day after finishing rTMS.Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken after finishing rTMS.
Athens Insomnia Scale First Follow-upBefore rTMS, two weeks after finishing rTMS.Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken two weeks after finishing rTMS.
Athens Insomnia Scale Second Follow-upBefore rTMS, four weeks after finishing rTMS.Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken four weeks after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension after rTMSBefore rTMS, up to one day after finishing rTMS.Change from baseline strength of the foot extension to the measurement taken after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension Second Follow-upBefore rTMS, four weeks after finishing rTMS.Change from baseline strength of the foot extension to the measurement taken four weeks after finishing rTMS.
Numeric Pain Severity Scale First Follow-upBefore rTMS, two weeks after finishing rTMS.Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken two weeks after finishing rTMS.
Numeric Pain Severity Scale Second Follow-upBefore rTMS, four weeks after finishing rTMS.Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after four weeks after finishing rTMS.

Countries

Poland

Contacts

Primary ContactJakub M Antczak, MD
jakub.antczak@uj.edu.pl+48 795 421 153
Backup ContactGabriela G Rusin, MD
gabriela.rusin@doctoral.uj.edu.pl+48 601 661 607

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026